MA28151A1 - Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations - Google Patents
Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisationsInfo
- Publication number
- MA28151A1 MA28151A1 MA29005A MA29005A MA28151A1 MA 28151 A1 MA28151 A1 MA 28151A1 MA 29005 A MA29005 A MA 29005A MA 29005 A MA29005 A MA 29005A MA 28151 A1 MA28151 A1 MA 28151A1
- Authority
- MA
- Morocco
- Prior art keywords
- imidazolyl derivatives
- bicyclic pyrazolyl
- pyrazolyl
- bicyclic
- imidazolyl
- Prior art date
Links
- -1 PYRAZOLYL Chemical class 0.000 title 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51828003P | 2003-11-07 | 2003-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28151A1 true MA28151A1 (fr) | 2006-09-01 |
Family
ID=34572986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29005A MA28151A1 (fr) | 2003-11-07 | 2006-05-05 | Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7151097B2 (enExample) |
| EP (1) | EP1682554A1 (enExample) |
| JP (2) | JP4056549B2 (enExample) |
| KR (1) | KR20060086396A (enExample) |
| CN (1) | CN1886407A (enExample) |
| AP (1) | AP2006003601A0 (enExample) |
| AR (1) | AR046831A1 (enExample) |
| AU (1) | AU2004286909A1 (enExample) |
| BR (1) | BRPI0416299A (enExample) |
| CA (1) | CA2544752A1 (enExample) |
| CR (1) | CR8387A (enExample) |
| DO (1) | DOP2004001024A (enExample) |
| EA (1) | EA009742B1 (enExample) |
| EC (1) | ECSP066549A (enExample) |
| GT (1) | GT200400226A (enExample) |
| HR (1) | HRP20060166A2 (enExample) |
| IL (1) | IL175283A0 (enExample) |
| IS (1) | IS8426A (enExample) |
| MA (1) | MA28151A1 (enExample) |
| MX (1) | MXPA06005023A (enExample) |
| NL (1) | NL1027434C2 (enExample) |
| NO (1) | NO20062618L (enExample) |
| OA (1) | OA13280A (enExample) |
| PA (1) | PA8616801A1 (enExample) |
| PE (1) | PE20050576A1 (enExample) |
| TN (1) | TNSN06129A1 (enExample) |
| TW (2) | TW200716135A (enExample) |
| WO (1) | WO2005044822A1 (enExample) |
| ZA (1) | ZA200603594B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| US7094572B2 (en) * | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| US20070260056A1 (en) * | 2004-09-27 | 2007-11-08 | Brandt Thomas A | Process for Preparing Bicyclic Pyrazolyl |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| CA2605479A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Products Inc. | Acylaminobicyclic heteroaromatic compounds and uses thereof |
| JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
| US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
| US8378096B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| US7872006B2 (en) | 2005-10-21 | 2011-01-18 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity |
| WO2007060525A2 (en) | 2005-11-28 | 2007-05-31 | Pfizer Products Inc. | Process for preparing bicyclic pyrazolyl and imidazolyl compounds |
| SG185849A1 (en) * | 2006-02-23 | 2012-12-28 | Pfizer Ltd | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| EP2727585A1 (en) * | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo screening method |
| WO2008048648A2 (en) * | 2006-10-17 | 2008-04-24 | Acadia Pharmaceuticals Inc. | Cb1-modulating compounds and their use |
| CN101583593A (zh) | 2006-11-13 | 2009-11-18 | 辉瑞产品公司 | 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途 |
| US20090062253A1 (en) * | 2007-08-31 | 2009-03-05 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| AU2009278838B2 (en) * | 2008-08-06 | 2013-07-25 | Pfizer Limited | Diazepine and diazocane compounds as MC4 agonists |
| US9549006B2 (en) * | 2013-07-31 | 2017-01-17 | Cisco Technology, Inc. | Self-adaptive sample period for content sharing in communication sessions |
| WO2015070007A1 (en) * | 2013-11-08 | 2015-05-14 | Incyte Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
| WO2020060761A2 (en) | 2018-09-04 | 2020-03-26 | Skodda Anja | Pet food formulation with cannabinoids |
| US11504416B2 (en) | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
| US12302903B2 (en) * | 2019-08-09 | 2025-05-20 | Nihon Nohyaku Co., Ltd. | Oxazepinone derivative, agricultural/horticultural insecticide containing the same, and method for using the same |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| EP1421077A4 (en) | 2001-08-31 | 2004-11-17 | Univ Connecticut | NEW PYRAZOLANALOGS ON CANNABINOID RECEPTORS |
| JP2005504100A (ja) | 2001-09-24 | 2005-02-10 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満の治療のための１，５，６，７−テトラヒドロピロロ［３，２−ｃ］ピリジン誘導体の製造法および使用 |
| GB0207249D0 (en) | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| JP2006506366A (ja) | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| WO2004098520A2 (en) | 2003-05-01 | 2004-11-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MXPA05011922A (es) | 2003-05-07 | 2006-02-17 | Pfizer Prod Inc | Ligandos del receptor de cannabinoides y sus usos. |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US20050026983A1 (en) | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| US20070260056A1 (en) * | 2004-09-27 | 2007-11-08 | Brandt Thomas A | Process for Preparing Bicyclic Pyrazolyl |
-
2004
- 2004-10-22 US US10/971,599 patent/US7151097B2/en not_active Expired - Fee Related
- 2004-10-25 EP EP04769741A patent/EP1682554A1/en not_active Withdrawn
- 2004-10-25 CN CNA2004800352698A patent/CN1886407A/zh active Pending
- 2004-10-25 MX MXPA06005023A patent/MXPA06005023A/es not_active Application Discontinuation
- 2004-10-25 EA EA200600647A patent/EA009742B1/ru not_active IP Right Cessation
- 2004-10-25 KR KR1020067008880A patent/KR20060086396A/ko not_active Abandoned
- 2004-10-25 JP JP2006538974A patent/JP4056549B2/ja not_active Expired - Fee Related
- 2004-10-25 CA CA002544752A patent/CA2544752A1/en not_active Abandoned
- 2004-10-25 OA OA1200600145A patent/OA13280A/en unknown
- 2004-10-25 HR HR20060166A patent/HRP20060166A2/xx not_active Application Discontinuation
- 2004-10-25 BR BRPI0416299-4A patent/BRPI0416299A/pt not_active IP Right Cessation
- 2004-10-25 AP AP2006003601A patent/AP2006003601A0/xx unknown
- 2004-10-25 WO PCT/IB2004/003522 patent/WO2005044822A1/en not_active Ceased
- 2004-10-25 AU AU2004286909A patent/AU2004286909A1/en not_active Abandoned
- 2004-11-02 PA PA20048616801A patent/PA8616801A1/es unknown
- 2004-11-02 TW TW095142275A patent/TW200716135A/zh unknown
- 2004-11-02 TW TW093133372A patent/TWI280245B/zh not_active IP Right Cessation
- 2004-11-03 DO DO2004001024A patent/DOP2004001024A/es unknown
- 2004-11-04 PE PE2004001074A patent/PE20050576A1/es not_active Application Discontinuation
- 2004-11-04 GT GT200400226A patent/GT200400226A/es unknown
- 2004-11-05 NL NL1027434A patent/NL1027434C2/nl not_active IP Right Cessation
- 2004-11-05 AR ARP040104075A patent/AR046831A1/es not_active Application Discontinuation
-
2006
- 2006-04-21 IS IS8426A patent/IS8426A/is unknown
- 2006-04-27 IL IL175283A patent/IL175283A0/en unknown
- 2006-05-05 ZA ZA200603594A patent/ZA200603594B/en unknown
- 2006-05-05 MA MA29005A patent/MA28151A1/fr unknown
- 2006-05-05 CR CR8387A patent/CR8387A/es not_active Application Discontinuation
- 2006-05-05 EC EC2006006549A patent/ECSP066549A/es unknown
- 2006-05-05 TN TNP2006000129A patent/TNSN06129A1/fr unknown
- 2006-06-07 NO NO20062618A patent/NO20062618L/no not_active Application Discontinuation
- 2006-09-07 US US11/470,695 patent/US20070027133A1/en not_active Abandoned
-
2007
- 2007-07-12 JP JP2007183117A patent/JP2007302685A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA28151A1 (fr) | Derives de pyrazolyle et d'imidazolyle bicycliques et leurs utilisations | |
| TNSN05190A1 (fr) | DERIVES DE PYRAZOLO [1,5-a][1,3,5] TRIAZINE SERVANT DE LIGANDS DES RECEPTEURS DE CANNABINOIDES | |
| MXPA05007938A (es) | Ligandos de receptores de cannabinoides y usos de los mismos. | |
| TW200503723A (en) | Cannabinoid receptor ligands and uses thereof | |
| TW200510419A (en) | Cannabinoid receptor ligands and uses thereof | |
| MXPA05011362A (es) | Ligandos de receptor cannabinoide y usos de los mismos. | |
| MXPA05013294A (es) | Ligandos del receptor de cannabinoides y usos de los mismos. | |
| EA200970326A1 (ru) | Алкильные производные в качестве метаботропных рецепторов глутамата | |
| MY140010A (en) | Purine compounds and use thereof as cannabinoid receptor ligands | |
| KR102684364B1 (ko) | 질환의 치료를 위한 kdm1a 저해제 | |
| MA27428A1 (fr) | Derives de pyrimidine et leur utilisation en tant que modulateurs cb2 | |
| PA8601201A1 (es) | Ligandos del receptor cannabinoide y usos de los mismos | |
| MA27668A1 (fr) | 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire | |
| MA29693B1 (fr) | Derives de xanthine en tant qu'agonistes hm74a selectifs | |
| ATE405558T1 (de) | Ketolactam-verbindungen und ihre verwendung | |
| TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
| ATE345329T1 (de) | Pyridinderivate als modulatoren des cb2-rezeptors | |
| MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
| MA30077B1 (fr) | 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines | |
| MA28680B1 (fr) | 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines | |
| ATE411296T1 (de) | Imidazolinderivate mit cb1-antagonistischer wirkung | |
| ATE496922T1 (de) | Mglur1-antagonisten als therapeutische wirkstoffe | |
| ATE340785T1 (de) | 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren | |
| ATE407119T1 (de) | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors | |
| EA200870074A1 (ru) | Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1 |